9999999997-15-012388.txt : 20150818
9999999997-15-012388.hdr.sgml : 20150818
20150804163708
ACCESSION NUMBER: 9999999997-15-012388
CONFORMED SUBMISSION TYPE: CT ORDER
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20150804
DATE AS OF CHANGE: 20150804
20150804
20150804
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: TG THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001001316
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 363898269
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CT ORDER
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32639
FILM NUMBER: 151026047
BUSINESS ADDRESS:
STREET 1: 787 SEVENTH AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10019
BUSINESS PHONE: (212) 554-4484
MAIL ADDRESS:
STREET 1: 787 SEVENTH AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10019
FORMER COMPANY:
FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030310
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC
DATE OF NAME CHANGE: 20000330
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19960703
CT ORDER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-)>+CS],-"C0R(# @;V)J#3P\+TQI;F5AF4@-34O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)D$&!@
M8F#R A(,4X $XWT@P1(()-C5@,0G P8F1H:=(%D&1G3B/^.L/P !!@"SPP;D
M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @
M(" @#0HU-" P(&]B:@T\/"]#(#8Y+T9I;'1E8F!@8&%@8(IF *>"@94P,@
MDN5H0!9C@6(&AOL,W R7!E+T]B
M:E-T;3X^>>Z
MD,S0V39;-T0J.JO*=C*I?CU<:&W11P1C# L\HG>6[8KMR[M%LUGF[W-#;JMYE6S3==XP,8_2FS;;%
M\KI<;W/"Z+S-=]\(EPE=O#SE& N4Z^*IK6KZO=^)TN;JRNT3]@TAQ[[^L5Q6
MJZ)#$ ' :%A+@"7Z?]!9"'<,&
M.'LJ&3%"N"$S^/3KA/- 4MH48V$-OE2I+A;>?9Q[USK9JX,;B8O*:%/:\D ,
M2;IDY0K[9VP/.?W:]FOO#SF.J(Q\2*IO /I3181@^-3PU'US=,3#GT#0-9S,$XGI/>9P8:; YM*T2]]
M4XUK@AJ8=?8NW^@!.CJD,<()XDA$P(U$"$D'9AS(^A$9 \8GG.0!0 PT:0R8
M@AAA$@[54>G>I 0,.8\H2T%^G<;^I?PF^_++S'GR^Z;RJB/*:]EIX57VI/">
MJ[GB?]9CJYRHLR4WS*:KX0&SFPJ^=Z?B>^#O!7+H[Q7X;'3'
M?!SDHN1R'GQ!FON\6'%5D@8Q0:7M53&H8R1 \;T2_AX?^J4X7G%/QHJK7#\%
MK"W<0WY0<2'NM.+"[E%P.7\EN%X17@EN:L_0VXB!26#K21@#;SNEMTK+?;WE
MK_56143V]\"# "Y
M!WQD#0IE;F1S=')E86T-96YD;V)J#30V(# @;V)J#3P\+T9I;'1E#F@@7L_?L/%P/6.Q_B#]X,1_"_XVG>'%Y 7?LWO,E
M+_IP6US>>W\5'WL!>@S062KR#.^F/Y2WNIMJAM#ND]17-TS1
M2!/X$3)R,.*R7\TO-C/GBXN_'\D!?X0'\/
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M-BXP_LD.PSS#]^P&;]?X?M+FOL"-Y2**C\65N8W"KM2IL')GG0@(IA8#X;E
M9)=XF6$T0X!\(W0ZN$1_0",K+CX^!R(,S7.HDC#',;VR?A]6]C2*:$IIT,0;
MS.X @,GYU4]MSE9S0[V6R["B%6*95>L=R%REQ$4AM?3ZN8AUT"&Y^;OS[XA/
M62?120Y)IU.!-;VHX=!BE<%QI$E^C4E@=#M'GLR>D3UCH).,B$\1\BDYY!-)
MR UHQQH?NSFE]^ *W7>5/@+)E)S8^@BY7RW*<@95.6UY@>#SM)[6$1\#7]8,
MK]LM$8BH-(%G'"O=R&;-]NLILNL9=?F./.+0_.L>KT;R[7+K+W@>&4$YC-=7F8CS>AE,(-P-A+Z&_R3T$"Y
M&,/=DI7/\ 8'\;%PB;%$R=/!-2P"XW\.H
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M%>G%G#208,-^C4IB8\N88&+6^UI]A<3:SI&72"#S @[O'X
M$ ,\@ 2+8_69@]O'SQYOW3=F::'UM?;)9^P2^)HZO1B
MQ+<;3<36KC'Z!L(&!#9WQ<,(NU*?'+X&:U4= KJVUALR8$;@-!AZ S4TMOO'
MYOFUI&R^>B G;%K%-+'IW;C*U(DF]X(Q#2N>SGBAT*:U,PGG&K=G#&=_(R2U
M6X*FDE8X%::XN*%,+57$EJ5K^38O7O/4K'8UI^%'
M$Q_M+FKUI9V%_X+5L%P:K#LZZ3 4J@$_=2T;U]Z@H$&_PZC[F2TI]>,=??+,
MIM3OE*W*343L"+6I1[O=4RBM[#)7,G7;"L"5ZT:VMCPUL-/:MV1'9".N=[FE
M_4^H37MR'P!Z[[^TVZH$FY%C9U#UE0;*!]WHJ4/(??04/S9;*<]
MTY2"IEKH(Q7:D<;1(D60=#K3H!+_]L2JN?WXNZ6&%BZ)*:Z,CN2,F=,E.0Y%
M]8&F$K1M07$RSO__<+"5ZA-,G4Y)?M 7'&!FNJXF);5JKAPG*R6J2^R9ZP 0
MT9*DZT=U.?Q1(3Z#VL()Y',_=CU*0VGQ>T^7?+W<2=:63K>)(>-*RE'RQJXE
MF6]<^965*+LJ>F%IZ[.D#;X*:CTA&^N56PA;:]H
M0/](G:"HLN4@GNK/@%AD\BA*KG7M4FR:7+V!-+B@J =('
M@-@H);4X&4A_ >+,\I("H#AC I MDI0-9H/4B62'!#D#V1U -E]):@5(C,$Y
MOZ"R*#,]HT3!T-+24L$Q)3\I52&XLK@D-;=8P3,O.;^H(+\HL20U!:@6:@<(
M\+L7)58JN"?FYB8J&.D9D>AR(@ H+"&LSR'@,&(4.X\00X#DTJ(R*).1R9B!
M 2# $G&."\-"F5N9'-T7!E+T]B
M:E-T;3X^?I299MN-O0X(0DCZ_5GB)SO(H 1/X($R#Q40EF S* H'
MUD+I,K (/D.PG,ESL#EXSVL%5.C!.JA*CJ1G.&=Y)BLX5'&M'" O6?* EJO/
M #F"2, _BX[7.4I9!5AP+1"0P505D/:0I^>8EWL+R+R"P\2\PI5 S'.\2V*>
M*PB(>8[?1\PKB0_!O-(C$/,\PXEYWO$1F5?QL3AB*][GQ86YY>-G<&?6S1BZ
MN!E#X%;\.[$*K_$V',&:N_X0OC4#MRDE-L7[9C.YR'
M0QC_GMBPZ:O^->W>W'=/83R3%HO_2>I\[S/SM>EV'Y:K3_?U1]9\^@YVD.[)Z459ORNI5
M6;TKJY=E];90;PO?\4WI;:'>%NIMH=X6ZFVAWA:J;/T68 !8LQ??#0IE;F1S
M=')E86T-96YD;V)J#3(@,"!O8FH-/#PO3&5N9W1H(#,Y,#(O4W5B='EP92]8
M34PO5'EP92]-971A9&%T83X^G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A
M('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @
M0V]R92 U+C0M8S P-2 W."XQ-#&UL;G,Z>&UP34T](FAT=' Z+R]N&%P+S$N,"]M;2\B
M"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO&UL;G,Z<&1F/2)H='1P.B\O;G,N
M861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @(" @(" @("!X;6QN&UP
M.DUE=&%D871A1&%T93XR,#$U+3 X+3 T5#$V.C(Y.C,S+3 T.C P/"]X;7 Z
M365T861A=&%$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%C&UP34TZ&UP34TZ"UD969A=6QT(B\^"B @(" @(" @(" @
M(#PO"UD969A=6QT(B\^"B @(" @(" @
M(" @(#PO7=O#I3;W5R
M8V5-;V1I9FEE9#X*(" @(" @(" @/'!D9G@Z0V]M<&%N>3Y314,\+W!D9G@Z
M0V]M<&%N>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO7!E+T]B:E-T;3X^79,OOG5>F2[@_;
M]G*_+&-AM,%36]F LIJF8$8P@=R,TR++!I G ,EW%8U%PU3;(';5:FNOR,(8
M<2(61V*G]!K[5PQ/J?26W']QQ^2Z!B/IJ,8/*#:^9LM]-(>@])XZ;C Z_N31
M_4 II(69Q$%77[ )\>S@PPVEFL_? @P /)Q'4PT*96YDF4@-#(O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F( B9&_C0&
M)@:FJ4!"H!M(,/:!"#&@Q-WK0!8# ^,0()CN PE&!H P BT05;#0IE;F1S
D=')E86T-96YD;V)J#7-T87)T>')E9@T*,3$V#0HE)45/1@T*
end